Slovenia’s Krka Says Court Rules It Breached AstraZeneca Patent

Krka Group d.d., Slovenia’s biggest drug company, said an Oslo court ruled that its Swedish unit breached AstraZeneca Plc (AZN)’s patent over the drug esomeprazole.

The Norwegian court ruled Krka infringed the patent because the drug contained an optical purity above 98 percent, the Novo mesto, Slovenia-based company said in a regulatory statement today. Krka said it was ordered to pay AstraZeneca about 1.9 million euros ($2.5 million) to compensate for lost profit from the reflux drug.

Krka said it will appeal the decision.

To contact the reporter on this story: Boris Cerni in Ljubljana at bcerni@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.